

Frame 1

00:00 – 00:02



JORDAN VO: I'm Jordan and these...

SUPER: Patient portrayal.

Frame 2

00:02 – 00:03




JORDAN VO: ...are my breasts.

SUPER: Patient portrayal.

Frame 3

00:03 – 00:05



JORDAN VO: We've been through some big changes.

Frame 4

00:05 – 00:07



JORDAN VO: Divorce...

Frame 5

00:07 – 00:08

JORDAN VO:a new grandson...



Frame 6

00:08 – 00:10

JORDAN VO: ...and as my next chapter began...




Frame 7

00:10 – 00:13

JORDAN VO: ...metastatic breast cancer. Then I learned about KISQALI...

SUPER: KISQALI® (ribociclib) is a treatment for adults with HR+, HER2- metastatic breast cancer in combination with a nonsteroidal aromatase inhibitor (NSAI) as the first endocrine-based therapy.

GRAPHIC: KISQALI logo




JORDAN VO: ...a pill that stops cancer from growing...

SUPER: KISQALI® (ribociclib) is a treatment for adults with HR+, HER2- metastatic breast cancer in combination with a nonsteroidal aromatase inhibitor (NSAI) as the first endocrine-based therapy.

GRAPHIC: KISQALI logo

Frame 9

00:15 – 00:16

**JORDAN VO:** ...and can help me live longer.**SUPER:** KISQALI® (ribociclib) is a treatment for adults with HR+, HER2- metastatic breast cancer in combination with a nonsteroidal aromatase inhibitor (NSAI) as the first endocrine-based therapy.**GRAPHIC:** KISQALI logo


Frame 10

00:16 – 00:18

**JORDAN VO:** Since then, I drove cross country...**SUPER:** Progression-free survival (PFS) and overall survival (OS) were the respective primary and secondary end points of the clinical trials. PFS is the amount of time cancer doesn't grow or spread while on treatment. OS is the length of time patients are alive from the start of treatment.**GRAPHIC:** KISQALI logo


Frame 11

00:18 – 00:20

**JORDAN VO:** ...finished a degree...**SUPER:** Progression-free survival (PFS) and overall survival (OS) were the respective primary and secondary end points of the clinical trials. PFS is the amount of time cancer doesn't grow or spread while on treatment. OS is the length of time patients are alive from the start of treatment.**GRAPHIC:** KISQALI logo

Frame 12

00:20 – 00:23

**JORDAN VO:** ...and finally saw my favorite band.**SUPER:** Progression-free survival (PFS) and overall survival (OS) were the respective primary and secondary end points of the clinical trials. PFS is the amount of time cancer doesn't grow or spread while on treatment. OS is the length of time patients are alive from the start of treatment.**GRAPHIC:** KISQALI logo

Frame 13

00:23 – 00:29




Postmenopausal women taking KISQALI plus an NSAI lived for 63.9 months vs 51.4 months on an NSAI alone. Premenopausal women taking KISQALI with an NSAI and goserelin lived 58.7 months vs 47.7 months on an NSAI and goserelin alone.

KISQALI
ribociclib 200 mg tablets

Frame 14

00:29 – 00:30




KISQALI may cause serious skin reactions, liver problems, and low white blood cell counts that may result in serious infections.

KISQALI
ribociclib 200 mg tablets

Frame 15

00:30 – 00:33




KISQALI may cause serious skin reactions, liver problems, and low white blood cell counts that may result in serious infections.

KISQALI
ribociclib 200 mg tablets

Frame 16

00:33 – 00:35



KISQALI may cause serious skin reactions, liver problems, and low white blood cell counts that may result in serious infections.

KISQALI
ribociclib 200 mg tablets

NARRATOR VO: KISQALI with an aromatase inhibitor is for adults with HR-positive, HER2-negative metastatic breast cancer.

SUPER: Postmenopausal women taking KISQALI plus an NSAI lived for 63.9 months vs 51.4 months on an NSAI alone. Premenopausal women taking KISQALI with an NSAI and goserelin lived for 58.7 months vs 47.7 months on an NSAI and goserelin alone.

GRAPHIC: KISQALI logo

NARRATOR VO: KISQALI may cause serious skin...

SUPER: KISQALI may cause serious skin reactions, liver problems, and low white blood cell counts that may result in serious infections.

GRAPHIC: KISQALI logo

NARRATOR VO: ...reactions, liver problems, and low white blood cell counts...

SUPER: KISQALI may cause serious skin reactions, liver problems, and low white blood cell counts that may result in serious infections.

GRAPHIC: KISQALI logo

NARRATOR VO: ...that may result in serious infections.

SUPER: KISQALI may cause serious skin reactions, liver problems, and low white blood cell counts that may result in serious infections.

GRAPHIC: KISQALI logo

Frame 17

00:35 – 00:39




NARRATOR VO: Life-threatening lung problems and abnormal heartbeats can occur. Your doctor should test your heart and blood...

SUPER: Life-threatening lung problems and abnormal heartbeats can occur. Your doctor should test your heart and blood before and during treatment.

GRAPHIC: KISQALI logo

Frame 18

00:39 – 00:41




NARRATOR VO: ...before and during treatment.

SUPER: Life-threatening lung problems and abnormal heartbeats can occur. Your doctor should test your heart and blood before and during treatment.

GRAPHIC: KISQALI logo

Frame 19

00:41 – 00:44




NARRATOR VO: Tell your doctor if you have new or worsening cough, chest pain,...

SUPER: Tell your doctor if you have new or worsening cough, chest pain, or dizziness.

GRAPHIC: KISQALI logo

Frame 20

00:44 – 00:45




NARRATOR VO: ...or dizziness.

SUPER: Tell your doctor if you have new or worsening cough, chest pain, or dizziness.

GRAPHIC: KISQALI logo

Frame 21

00:45 – 00:51




NARRATOR VO: Before taking KISQALI, tell your doctor all your medical conditions, medicines you take, and if you're breastfeeding, pregnant, or planning to be...

SUPER: Before taking KISQALI, tell your doctor all your medical conditions, medicines you take, and if you're breastfeeding, pregnant, or planning to be – as it can harm an unborn baby.

GRAPHIC: KISQALI logo

Frame 22

00:51 – 00:53




NARRATOR VO: ... – as it can harm an unborn baby.

SUPER: Before taking KISQALI, tell your doctor all your medical conditions, medicines you take, and if you're breastfeeding, pregnant, or planning to be – as it can harm an unborn baby.

GRAPHIC: KISQALI logo

Frame 23

00:53 – 00:55




NARRATOR VO: Common side effects include nausea, headache, and tiredness

SUPER: Common side effects include nausea, headache, and tiredness.

GRAPHIC: KISQALI logo

Frame 24

00:55 – 01:00



JORDAN VO: I'm more than just breast cancer, and I have a lot more to go.

SUPER:

Individual results may vary. By prescription only.

*For eligible commercially insured patients.

Limitations apply.

Visit KISQALI.com to learn about costs and how Novartis can help. 1-888-669-6682

GRAPHICS:

More life for living

KISQALI Logo (animated)

Get started for as little as \$0*

QR Code

Novartis Logo

GLOBAL: Upon scanning the QR Code, users will be driven to:

<https://us.kisqali.com/metastatic-breast-cancer/novartis-patient-support>